ClinicalTrials.gg

Program

Pexerelgon

Also written as “AZD5462”, “AZD5462 film-coated tablet” and “[14C]AZD5462 Solution for Infusion”.

Its studies are mostly in Heart Failure · Renal Insufficiency, led by AstraZeneca.

Furthest: phase 2, since Feb 16, 20247 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca70 open or runningphase 2since Feb 16, 2024Jul 29, 2021none ahead
  • Named in AstraZeneca’s own pipeline as AZD5462, phase 2, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel and quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT04994106 · 98 enrolled · United States
  2. May 24, 2022Phase 1 study in Healthy ParticipantsNCT05395117 · 32 enrolled · United States
  3. Aug 22, 2022Phase 1 study in Healthy ParticipantsNCT05512806 · 16 enrolled · United States
  4. Feb 16, 2024Phase 2 study in Chronic Heart FailureNCT06299826 · 375 enrolled · United States, Bulgaria, Czechia and more
  5. Sep 13, 2024Phase 1 study in Renal InsufficiencyNCT06639087 · 8 enrolled · Bulgaria
  6. Oct 25, 2024Phase 1 study in Renal InsufficiencyNCT06661733 · 16 enrolled · Bulgaria
  7. May 5, 2025Phase 1 study in Heart FailureNCT06989983 · 8 enrolled · United Kingdom

TargetBeta

“A mimetic of the endogenous heterodimeric insulin-like peptide relaxin, with potential vasodilating, cardioprotective and anti-fibrotic activities. Upon administration, pexerelgon mimics relaxin and may bind to relaxin receptor 1 (relaxin family peptide receptor 1; RXFP1). This may activate multi…”NCIt, read by Claude

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06989983Heart Failure · United Kingdom1CompletedJun 25, 20258
NCT06661733Renal Insufficiency · Bulgaria1CompletedDec 23, 202416
NCT06639087Renal Insufficiency · Bulgaria1TerminatedMay 29, 20258
NCT06299826Chronic Heart Failure · United States, Bulgaria, Czechia and more2CompletedFeb 10, 2026375
NCT05512806Healthy Participants · United States1CompletedNov 7, 202216
NCT05395117Healthy Participants · United States1CompletedSep 12, 202232
NCT04994106Healthy Participants · United States1CompletedSep 20, 202298

How it is read

Names in the registry

  • “AZD5462”, 6 entries
  • “AZD5462 film-coated tablet”, 1 entry
  • “[14C]AZD5462 Solution for Infusion”, 1 entry
  • “[14C]AZD5462 Oral Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.